These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2874784)

  • 1. Cellular migration, proliferation, and contraction. An in vitro approach to a clinical problem--proliferative vitreoretinopathy.
    Verdoorn C; Renardel de Lavalette VW; Dalma-Weizhausz J; Orr GM; Sorgente N; Ryan SJ
    Arch Ophthalmol; 1986 Aug; 104(8):1216-9. PubMed ID: 2874784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxol, cytochalasin B and colchicine effects on fibroblast migration and contraction: a role in glaucoma filtration surgery?
    Joseph JP; Grierson I; Hitchings RA
    Curr Eye Res; 1989 Feb; 8(2):203-15. PubMed ID: 2565797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.
    Kirmani M; Santana M; Sorgente N; Wiedemann P; Ryan SJ
    Retina; 1983; 3(4):269-72. PubMed ID: 6201971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro.
    Cai J; Wei R; Ma X; Zhu H; Li Y
    Int Ophthalmol; 2001; 24(4):225-31. PubMed ID: 12678400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition of lens epithelial cell proliferation and migration.
    McDonnell PJ; Krause W; Glaser BM
    Ophthalmic Surg; 1988 Jan; 19(1):25-30. PubMed ID: 3340398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of human Tenon's capsule fibroblasts and rabbit dermal fibroblasts with non-carcinogenic N-alkylated anthracyclines.
    Steinhorst UH; Chen EP; Freedman SF; Machemer R; Hatchell DL
    Graefes Arch Clin Exp Ophthalmol; 1994 Jun; 232(6):347-54. PubMed ID: 8082842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collagen gel contraction by cells associated with proliferative vitreoretinopathy.
    Guidry C; McFarland RJ; Morris R; Witherspoon CD; Hook M
    Invest Ophthalmol Vis Sci; 1992 Jul; 33(8):2429-35. PubMed ID: 1634340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms involved in retinal pigment epithelial cell chemotaxis.
    Campochiaro PA; Glaser BM
    Arch Ophthalmol; 1986 Feb; 104(2):277-80. PubMed ID: 2418812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collagen synthesis and cell growth in chick embryo fibroblasts: influence of colchicine, cytochalasin B and concanavalin A.
    Bodo M; Carinci P; Baroni T; Becchetti E; Bellucci C; Pezzetti F; Giammarioli M; Stabellini G; Arena N
    Cell Biol Int; 1996 Mar; 20(3):177-85. PubMed ID: 8673066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of slow Ca2+ channel blockers to enhance inhibition by taxol of growth of drug-sensitive and -resistant Chinese hamster ovary cells.
    Racker E; Wu LT; Westcott D
    Cancer Treat Rep; 1986 Feb; 70(2):275-8. PubMed ID: 2868790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models for assessing scar tissue inhibitors.
    van Bockxmeer FM; Martin CE; Constable IJ
    Retina; 1985; 5(1):47-60. PubMed ID: 4001590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of anticytoskeletal compounds on in vitro cytopathic effect, phagocytosis, and adhesiveness of Trichomonas vaginalis.
    Juliano C; Monaco G; Bandiera P; Tedde G; Cappuccinelli P
    Genitourin Med; 1987 Aug; 63(4):256-63. PubMed ID: 2888725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.
    Wiedemann P; Sorgente N; Bekhor C; Patterson R; Tran T; Ryan SJ
    Invest Ophthalmol Vis Sci; 1985 May; 26(5):719-25. PubMed ID: 3997421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and therapeutic aspects of proliferative vitreoretinopathy.
    Constable I
    Jpn J Ophthalmol; 1987; 31(4):513-20. PubMed ID: 2896260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin.
    Kumar A; Tewari HK; Bathwal DP; Khosla PK
    Indian J Ophthalmol; 1994 Mar; 42(1):31-5. PubMed ID: 7927629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease.
    Hui YN; Hu D
    Graefes Arch Clin Exp Ophthalmol; 1999 Jul; 237(7):601-5. PubMed ID: 10424311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation.
    Wiedemann P; Kirmani M; Santana M; Sorgente N; Ryan SJ
    Graefes Arch Clin Exp Ophthalmol; 1983; 220(5):233-5. PubMed ID: 6629017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxol for the treatment of proliferative vitreoretinopathy.
    van Bockxmeer FM; Martin CE; Thompson DE; Constable IJ
    Invest Ophthalmol Vis Sci; 1985 Aug; 26(8):1140-7. PubMed ID: 2862129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic human vitreous promotes contraction by fibroblasts. Implications for proliferative vitreoretinopathy.
    Hardwick C; Morris R; Witherspoon D; White M; Feist R; McFarland R; Guidry C
    Arch Ophthalmol; 1995 Dec; 113(12):1545-53. PubMed ID: 7487624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological modulation of human subconjunctival fibroblast behavior in vitro.
    Damji KF; Rootman J; Palcic B; Thurston G
    Ophthalmic Surg; 1990 Jan; 21(1):31-43. PubMed ID: 2325993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.